Researchers at the University of California, Davis, have identified distinct cell types within the amygdala that may hold the potential to revolutionise treatment for anxiety, depression, and other emotional disorders.
This discovery could pave the way for more focus therapies targeting the specific cells responsible for anxiety-related conditions, a major step forward in understanding and managing these complex disorders.
This findings were detail in the American Journal of Psychiatry on 30th October 2024, highlighting the amygdala’s role as a critical structure in emotion regulation and its potential as a focal point for therapeutic advances.
The report was publish on Psychiatry Online.
As per the research, Drew Fox, Associate Professor in UC Davis’ Department of Psychology, explain the amygdala’s fundamental role in processing emotions like fear and anxiety, pointing out that these conditions impact millions globally.
Despite the longstanding interest in whether amygdala size or structure links to emotional disorders, Drew Fox said that previous studies show limit correlation between overall amygdala size and anxiety or depression.
But, the focus is shifting toward the amygdala’s cellular composition, where certain clusters may serve distinct emotional functions and could be directly involve in the onset of anxiety and related disorders.
The UC Davis team, led by graduate student Shawn Kamboj in collaboration with Professor Cynthia Schumann from the UC Davis School of Medicine, use single-cell RNA sequencing to isolate specific cell clusters in both human and non-human primates.
This advance approach allow researchers to sort cells based on their gene expression patterns, identifying cells that likely contribute to emotional dysregulation.
By isolating genes actively express within each cell, the team map a comprehensive cellular profile that could help in translating findings from animal models to human applications.
Among their discoveries, researchers highlight cells expressing the FOXP2 gene, which they believe plays a ‘gatekeeper’ role within the amygdala.
Located at the amygdala’s edges, these FOXP2-positive cells are thought to regulate signals associated with anxiety.
In rodent models, this group of cells appears to act as a checkpoint, controlling the flow of information related to fear responses.
The team also identified Neuropeptide FF Receptor 2 (NPFFR2) in these cells, offering a promising target for future drug therapies.
This research could give advance treatment options by showing how specific cell types contribute to anxiety, potentially allowing for therapies aimed at ‘chokepoints’ in emotional processing.
As per Drew Fox, the aim is to develop interventions that specifically address the cells influencing anxiety, making way for highly target and effective treatments.
